Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07095114

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

Sponsor: Barbara Ann Karmanos Cancer Institute

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are: * Is the Magic Ink as safe as standard tattoo ink * Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.

Official title: A Phase I/II Study of Disappearing Markers for Daily Radiation Treatment Delivery

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-08-18

Completion Date

2026-08-08

Last Updated

2025-09-18

Healthy Volunteers

Conditions

Ductal Carcinoma in Situ Stage I Breast Cancer Stage II Breast Cancer Stage III Breast Cancer

Interventions

OTHER

Magic Ink

A novel ink that is only visible when exposed to Ultraviolet light and can be hidden using white light will be inserted into the dermis to tattoo a radiation guidance tattoo into the skin of the participant

Inclusion Criteria: * Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery * Participants must be 18 years of age or older * Participant must be able to understand a written informed consent document and be willing to sign it * Participant must be assigned female at birth * Participant must have a Karnofsky performance score of greater than or equal to 70% * Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation * Agree to practice true abstinence from sexual intercourse * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship) * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception. * For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6 Exclusion Criteria: * Participants who have received prior radiation treatment to the affected breast. * Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink * Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study * Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued * Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Locations (1)

Karmanos Cancer Institute

Detroit, Michigan, United States